secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2026-05-13T11:34:07+00:00
Accession:  0001326190-26-000037
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q1 net loss $22.6M; cash $535M; PERFORMA Phase 3 MASH trial initiation in H2 2026
--------------------------------------------------------------------------------

- Net loss of $22.6M ($0.18 loss per share) vs $19.6M ($0.26) in Q1 2025; R&D $16.2M, G&A $8.1M.
- Cash, equivalents and short-term investments $332M at Mar 31, 2026; $535M at Apr 30, 2026 after $225M public offering.
- Initiation of PERFORMA Phase 3 MASH trial planned for H2 2026; topline RECLAIM Phase 2 AUD data expected Q3 2026; RESTORE Phase 2 ALD enrollment completion Q3 2026.
- Pemvidutide received Breakthrough Therapy Designation for MASH; EASL presentations on May 28, 2026 including 48-week IMPACT data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/0001326190-26-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-26-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer